Our Team

Leadship Team

Image

JACK

"JACK" Jiagang Zhao, PhD, Founder and CEO

Dr. Zhao previously was a research investigator at Shiley Eye Institute of University of California San Diego.  Dr. Zhao worked as a scientist with a leadership role in Tularik (acquired by Amgen) and Anadys Pharmaceuticals (acquired by Roche). He is the inventor of the human retinal stem cell technology patent.

Dr. Zhao completed his graduate work in Icahn School of Medicine at Mt. Sinai, and subsequently received his postdoctoral training in molecular neurobiology at Salk Institute.

Image

Ying Wu

Ying Wu, MD. Co-founder and Vice President

Dr. Wu has over 27 years of biomedical R&D experience in both academia and industry settings across many fields of biomedical research and drug discovery.

Dr. Wu obtained her MD and clinical training from Bethune Medical Science University in China.  After moving to United States, she invented in vitro coupled transcription and translation system at Public Health Research Institute in New York City.  She also worked with AIDS research pioneer Dr. David Ho at Aaron Diamond AIDS Research Center in New York before coming to San Diego.

Image

Keith Bryant

Keith Bryant, MBA, Chief Business Officer

Initially a Booz.Allen & Hamilton strategy consultant in New York focused on big pharma, Keith Bryant has over 20 years’ experience in Business Planning, Business Development and Finance in San Diego biotech across many therapeutic areas and scientific modalities. He has closed a total of 10 deals from both sides of the table including a $1.4 billion out-licensing. He is a past member of the leadership teams of 4 mid-sized public companies. He holds an MBA in Finance from New York University and other degrees from Texas Tech University and Yale.

Board Members

Peng Cheng

Peng Cheng, Ph.D.

Dr. Peng Cheng is the Managing Partner of SV Tech Ventures.

Peng was most recently Founder and Managing Director of Brilliance Capital, a venture capital company focusing on investment in early-stage technology companies, ranging from networking, wireless, semiconductor, and biotech. Prior to that, he was the senior manager at Intel from 1990 to 2001, where he was involved in research and development of deep sub-micron device and processing, Silicon-on-Insulator, spacer gate, and Micro-Electro-Mechanical System (MEMS). He is the holder of more than 30 U.S. patents.

Dr. Cheng received his Ph.D. in Physics from Stanford University in 1990 & B.S. in Physics from Peking University in 1985.

Guo-Liang Yu

Guo-Liang Yu, Ph.D.

Dr. Guo-Liang Yu is a co-founder and currently CEO of Apollomics, Inc. He is a venture partner at Orbimed Venture LLC and the Executive Chairman of Crown Bioscience Inc. Dr. Yu co-founded Epitomics Inc., an antibody-based Biotechnology Company recently acquired by Abcam at $170 M. He served as Chairman, President and CEO of Epitomics Inc. for 10 years. Dr. Yu’s success is driven by his scientific curiosity and a passion for translating scientific discovery to real products.

He moved from China to the US to pursue advanced training after graduating from Fudan University in 1984. He obtained his PhD from UC Berkeley where he contributed to the discovery of telomerase and its mechanism of action in Dr. Blackburn’s lab. Drs. Blackburn and Greider received the Nobel Prize in 2009 for their discovery. After graduating, Dr. Yu joined Dr. Frederick Ausubel’s lab at Harvard to pursue the question of how plants defend themselves against pathogens without an immune system. He identified the first plant disease resistance gene.

Yajun Xu

Yajun Xu, Ph.D.

Yajun Xu is currently president of Shangpharma Investment Group.  She also serves as Sr. advisor for Shangbay Capital, co-founder (Epimab Inc.), board member and advisor on numerus biotech companies in U.S. and China. Previously, she was Sr. vice president of corporate development of Shangpharma, executive vice president of biology and pre-clinical service at Chempartner in Shanghai, China. Prior to Joining Shangpharma, Yajun was director of inflammation at Millennium pharma Inc. and senior scientist at BASF Bioresearch Corp. (now AbbVie Bioresearch Corp.). She received her Ph.D. in Biochemistry at Brandeis University and postdoctoral training at Harvard School of Public Health.

Ying Wu

Ying Wu, MD.

Dr. Wu has over 27 years of biomedical R&D experience in both academia and industry settings across many fields of biomedical research and drug discovery.

Dr. Wu obtained her MD and clinical training from Bethune Medical Science University in China.  After moving to United States, she invented in vitro coupled transcription and translation system at Public Health Research Institute in New York City.  She also worked with AIDS research pioneer Dr. David Ho at Aaron Diamond AIDS Research Center in New York before coming to San Diego.

JACK

"JACK" Jiagang Zhao, Ph.D.

Dr. Zhao previously was a research investigator at Shiley Eye Institute of University of California San Diego.  Dr. Zhao worked as a scientist with a leadership role in Tularik (acquired by Amgen) and Anadys Pharmaceuticals (acquired by Roche). He is the inventor of the human retinal stem cell technology patent.

Dr. Zhao completed his graduate work in Icahn School of Medicine at Mt. Sinai, and subsequently received his postdoctoral training in molecular neurobiology at Salk Institute.  

Scientific Advisory Board

Natalie Afshari M.D., F.A.C.S., Adviser

Dr. Afshari is Professor of Ophthalmology and holds Stuart I. Brown MD Chair in Ophthalmology in Memory of Donald P. Shiley at the Shiley Eye Institute of University of California San Diego.

Connect with us

11107 Roselle Street, Ste 210, San Diego, CA 92121

  • dummy info@aplinebt.com

Newsletter

Enter your email and we'll send you more information

Search